Good afternoon, everyone, and thank you for standing by, and welcome to the Corvus Pharmaceuticals Fourth Quarter and Full Year 2025 Business Update and Financial Results Conference Call. [Operator ...
Earnings call Nektar ended 2025 with $245.8M in cash and no debt, bolstered by an additional $476M in early 2026. REZPEG advanced to phase 3 in atopic dermatitis with phase 3 initiation set for June ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results